Recent Developments in the Field of 123I-Radiopharmaceuticals

H.-J. Machulla; E. J. Knust

doi:10.1055/s-0038-1624203

Nuklearmedizin - NuclearMedicine, Inhaltsverzeichnis

Nuklearmedizin 1984; 23(03): 111-118
DOI: 10.1055/s-0038-1624203

Originalarbeiten – Original Articles

Schattauer GmbH

Recent Developments in the Field of ¹²³I-Radiopharmaceuticals ^[*]

Neuere Entwicklungen auf dem Gebiet der ¹²³J-markierten Radiopharmazeutika

Autoren

H.-J. Machulla

¹From the Institut für Medizinische Strahlenphysik und Strahlenbiologie, Universitätsklinikum Essen, Essen, Federal Republic of Germany
E. J. Knust

¹From the Institut für Medizinische Strahlenphysik und Strahlenbiologie, Universitätsklinikum Essen, Essen, Federal Republic of Germany

Abstract

Summary

Due to its advantageous nuclear physical properties iodine-123 is an excellent label for radiopharmaceuticals very well suited for measurements by γ-cameras and single-photon emission tomography. The development of ¹²³I-radiopharmaceuticals should be based on a clear biochemical concept, reliable labelling procedures and careful pharmacokinetic studies in order to evaluate the physiological behaviour of the radioiodinated compounds being analogues of metabolic substrates. The development of ¹²³I-labelled fatty acids and biogenic amines clearly proved the successful use of ¹²³I for labelling compounds applied in medical diagnosis.

Zusammenfassung

Aufgrund seiner hervorragenden kernphysikalischen Eigenschaften stellt ¹²³J ein ausgezeichnetes Radionuklid zur Markierung von Radiopharmaka dar, die somit sehr gut geeignet sind für Messungen mit herkömmlichen γ-Kameras oder mittels der Single Photon Emission Tomography (SPECT). Voraussetzung für die Entwicklung von ¹²³J-Radiopharmaka sind klare biochemische Konzepte, zuverlässige Markierungsmethoden und pharmakokinetische Studien zur Ermittlung des physiologischen Verhaltens radiojodierter Verbindungen als Analoga metabolischer Substrate. Die Entwicklung ¹²³J-markierter Fettsäuren und biogener Amine beweist sehr deutlich die erfolgreiche Verwendungsmöglichkeit von ¹²³J zur Markierung von Verbindungen für die Anwendung in der nuklear-medizinischen Diagnose.

Volltext

Referenzen

References
1 Dudczak R, Kletter K, Frischauf H, Schmoliner R, Derfler K, Losert U. Myocardial turnover rates of (¹²³I)-heptadecanoic acid and p-(¹²³I-phenyl)-pentadecanoic acid. In Radioaktive Isotope in Klinik und Forschung, Band 15, 2. Teil. 1982. Höfer R. Hrsg.) 685-96 Egermann, Wien:
2 Dudczak R. Myokardszintigraphie mit ¹²³J-markierten Fettsäuren. Wien. klin. Wschr. 1983; 95 (Suppl. 143) 1-35.
3 Eisenhut M. Simple labelling of ωphenylfatty acids by iodine isotope exchange. Int. J. appl. Radiat. Isot. 1982; 33: 499-504.
4 Elmaleh D. R., Knapp F. F., Yasuda T, Coffey J. L., Kopiwoda S, Okada R, Strauss H. W. Myocardial imaging with 9-(^123mTe)-tellurahep-tadecanoic acid. J. nucl. Med. 1981; 22: 994-9.
5 Feinendegen L. E., Vyska K, Freundlieb C. h.r, Höck A, Machulla H-J, Kloster G, Stöcklin G. Non-invasive analysis of metabolic reactions in body tissues. The case of myocardial fatty acids. Eur. J. nucl. Med. 1981; 6: 191-200.
6 Franke L, Hanson R, Lee S. H., Seitz D. Radiohalodestannylation Labelling of substituted trialkylstannylarenes and ethylenes. J. nucl. Med. 1983; 24: 116.
7 Freundlieb C, Höck A, Vyska K, Feinendegen L. E., Machulla H-J, Stöcklin G. Myocardial imaging and metabolic studies with 17-^l23I-heptadecanoic acid. J. nucl. Med. 1980; 21: 1043-50.
8 Goodman M. M., Knapp Jr F. F., Callahan A. P., Ferren L. A. Synthesis and biological evaluation of 17-(¹³¹I)-iodo-9telluraheptadecanoic acid A potential myocardial imaging agent. J. med. Chem. 1982; 25: 613-8.
9 Goodman M. M., Knapp Jr F. F., Callahan A. P., Ferren L. A. A new wellretained myocardial imaging agen. Radioiodinated 15-(p-iodophenyl)-6tellurapentadecanoic acid. J. nucl. Med. 1982; 23: 904-8.
10 Goodman M. M., Cunningham E. B., Callahan A. P., Kirsch G, Knapp Jr F. F. Synthesis and evaluation of radioiodinated terminal p-iodophenyl-substituted aand ß-methyl-branched fatty acids: A new class of myocardial imaging agents. J. med. Chem. (submitted).
11 Hill T. C., Holman B. L., Lovett R, O’Leary D. H., Front D, Magistretti P, Zimmerman R. E., Moore S, Clouse M. E., Wu J. L., Lin T. H., Baldwin R. M. Initial experience with SPECT (single photon computerized tomography) of the brain using N-isopropyl-¹²³I-p-iodoamphetamine. J. nucl. Med. 1982; 23: 191-5.
12 Höck A, Freundlieb C, Vyska K, Lösse B, Erbel R, Feinendegen L. E. Myocardial imaging and metabolic studies with 17-¹²³I-heptadecanoic acid in patients with idiopathic congestive cardiomyopathy. J. nucl. Med. 1983; 24: 22-8.
13 Holman B. L., Zimmerman R. E., Schapiro J. R., Kaplan M. L., Jones A. G., Hill T. C. Biodistribution and dosimetry of N-isopropyl-p-(¹²³I)-iodoamphetamine in the primate. J. nucl. Med. 1983; 24: 922-31.
14 Kabalka G. W., Gooch E. E., Sastry K. A.R. Rapid and mild syntheses of radioiodine-labeled radiopharmaceuticals. J. nucl. Med. 1981; 22: 908-12.
15 Knapp Jr F. F., Ambrose K. R., Callahan A. P., Ferren L. A., Grigsby R. A., Irgolic K. J. Effects of chain length and tellurium position on the myocardial uptake of ^123mTe fatty acids. J. nucl. Med. 1981; 22: 988-93.
16 Knapp Jr F. F., Goodman M. M., Callahan A. P. Radioiodination of 15-(piodophenyl)-6-tellurapentadecanoic acid by triazene decomposition with radioiodide. J. lab. Comp. Radiopharm. (in press).
17 Kuhl D. E., Barrio J. R., Huang S. C., Selin C, Ackermann R. F., Lear J. L., Wu J. L., Lin T. H., Phelps M. E. Quantifying local cerebral blood flow by N-isopropyl-p-(‘²³I)-iodoamphetamine (IMP) tomography. J. nucl. Med. 1982; 23: 196-203.
18 Kulkarni P. V., Parkey R. W. Radioiodination of phenylpentadecanoic acid via an organothallium intermediate. J. lab. Comp. Radiopharm. (in press).
19 Kung H. F., Blau M. Regional in tracellular pH shift. A proposed new mechanism for radiopharmaceutical uptake in brain and other tissues. J. nucl. Med. 1980; 21: 147-52.
20 Kung H. F., Tramposch K. M., Blau M. A new brain perfusion imaging agent: (¹²³I) HIPDM. N,N,N’-trimethylN’-(2-hydroxy-3-methyl-5-iodobenzyl)l,3propanediamine. J. nucl. Med. 1983; 24: 66-72.
21 Lassen N. A., Henriksen L, Holm S, Barry D. I., Paulson O. B., Vorstrup S, Rapin J, le Poncin-Lafitte M, Moretti J. L., Askienazy S, Raynaud C. Cerebral blood-flow tomography. ¹³³Xenon compared with N-isopropyl-amphetamine¹²³iodine. J. nucl. Med. 1983; 24: 17-21.
22 Livni E, Elmaleh D. R., Levy S, Brownell G. L., Strauss H. W. Beta-methyll-ⁿC-heptadecanoic acid. A new myocardial metabolic tracer for positron emission tomography. J. nucl. Med. 1982; 23: 169-75.
23 Machulla H-J, Läufer P, Stöcklin G. Radioanalytical quality control of ^UC-, ¹⁸Fand ¹²³I-labelled compounds and radiopharmaceuticals. J. radioanal. Chem. 1976; 32: 381-400.
24 Machulla H-J, Stöcklin G, Kupfernagel Ch., Freundlieb Ch., Höck A, Vyska K, Feinendegen L. E. Comparative evaluation of fatty acids labelled with ⁿC, ^34mCl, ⁷⁷Br and ¹²³I for metabolic studies of the myocardium. J. nucl. Med. 1978. 19 298-302.
25 Machulla H-J, Stöcklin G, Kupfernagel Ch., Vyska K, Höck A, Freundlieb C. h.r, Feinendegen L. E. Comparative studies of different labelled fatty acids for heart muscle metabolism. In Nuklearmedizin. 1978. Woldring M, Schmidt A. E. H. Hrsg.), S. 212-5 Schattauer, Stuttgart New York:
26 Machulla H-J, Marsmann M, Dutschka K. Biochemical concept and synthesis of a radioiodinated phenylfatty acid for in vivo metabolic studies of the myocardium. Eur. J. nucl. Med. 1980; 5: 171-3.
27 Machulla H-J, Marsmann M, Dutschka K. Radiopharmaceuticals. I. Synthesis of radioiodinated phenylfatty acids for studying myocardial metabolism. J. radioanal. Chem. 1980; 56: 253-61.
28 Machulla H-J, Marsmann M, Dutschka K, van Beuningen D. Radiopharmaceuticals. II. Radiobromination of phenylpentadecanoic acid and biodistribution in mice. Radiochem. radioanal. Letters. 1980; 42: 243-50.
29 Machulla H-J, Dutschka K, van Beuningen D, Chen T. Development of 15-(p-^l23I-phenyl)-pentadecanoic acid for in vivo diagnosis of the myocardium. J. radioanal. Chem. 1981; 65: 279-86.
30 Machulla H-J, Dutschka K. Iodination methods for routine preparation of 17-¹²³I-heptadecanoic acid and 15-(p-¹²³Iphenyl)-pentadecanoic acid. J. radioanal. Chem. 1981; 65: 123-30.
31 Machulla H-J, Chen T, Knust E. J., Dutschka K, Meissner P, Scharf-Bornhofen E, Blümchen G. 15-(p-¹²³I-phenyl)pentadecanoic acid as an indicator for myocardial metabolism. In Nuclear Medicine and Biology. 1982. Raynaud C. Ed.) Vol. II, 1385-9 Pergamon Press; Paris:
32 Machulla H-J. Radioactive labeling of fatty acids for metabolic studies. In Applications of Nuclear and Radiochemistry. 1982. Lambrecht R. M., Morcos N. Eds.) 325-41. Pergamon Press; New York:
33 Machulla H-J, Knust E. J., Baldwin R. M., Schmidt U, Dutschka K, Molls M. Radiopharmaceuticals. VI. Nisopropyl-p-¹²³I-amphetamine, accumulation and elimination in mice. Radiochem. radioanal. Letters. 1983; 57: 241-6.
34 Reske S. N., Biersack H. J., Lackner K, Machulla H-J, Knopp R, Hahn N, Winkler C. Assessment of regional myocardial uptake and metabolism of co-(p¹²³I-phenyl)-pentadecanoic acid with serial single-photon emission tomography. Nucl. Med. 1982; 20: 249-53.
35 Reske S. N. ¹²³I-Phenyl-Pentadecansäure Ein neuer Tracer zur Untersuchung des myokardialen Metabolismus freier Fettsäuren. Der Nuklearmediziner. 1983; 1: 25-16.
36 Reske S. N., Schmitz B, Machulla H-J, Sauer W, Knust E. J., Egge H, Winkler C. Myocardial metabolism of 15-(p^I23I-phenyl)-pentadecanoic acid compared to l-¹⁴C-palmitic acid. In Radioaktive Isotope in Klinik und Forschung, Band 16, 2. Teil. 1984. Höfer R. Hrsg.), S. 367-73 Egermann, Wien:
37 Schweickert R. Private Mitteilung. Kemforschungszentrum Karlsruhe, Sept. 1983
38 Van der Wall E. E., Heidendal G. A.K, den Hollander W, Westera G, Roos J. P. ¹²³I labeled hexadecanoic âcid in comparison with “‘thallium for myocardial imaging in coronary heart disease. A preliminary study. Eur. J. nucl. Med. 1980; 5: 401-5.
39 Van der Wall E. E., den Hollander W, Heidendal G. A. K., Westera G, Majid P. A., Roos J. P. Dynamic myocardial scintigraphy with ¹²³I-labeled free fatty acids in patients with myocardial infarction. Eur. J. nucl. Med. 1981; 6: 383-9.
40 Van d. e.r, Wall E. E., Heidendal G. A.K, den Hollander W, Westera G, Roos J. P. Metabolic myocardial imaging with ¹²³I-labeled heptadecanoic acid in patients with angina pectoris. Eur. J. nucl. Med. 1981; 6: 391-6.
41 Vyska K, Freundlieb C, Höck A, Feinendegen L. E., Machulla H-J, Stöcklin G. Myocardial imaging and measurement of myocardial fatty acid metabolism using (o-^l23I-heptadecanoic acid. Adv. Clin. Cardiol. 1980; 1: 422-36.
42 Weinreich R. Critical comparison of production methods for ¹²³I. In ¹²³I in Western Europe. 1976. Qaim S. M., Stöcklin G, Weinreich R. Eds.) 49-69. JülConf-20, August.
43 Winchell H. S., Horst W. D., Braun L. H., Oldendorf W. H., Hattner R, Parker H. N-Isopropyl-(^l23I)-p-iodoamphetamine. Single-pass brain uptake and washout; binding to brain synaptosomes; and localization in dog and monkey brain. J. nucl. Med. 1980; 21: 947-52.
44 Winchell H. S., Baldwin R. M., Lin T. H. Development of ¹²³I-labeled a mines for brain studies. Localization of ^l23Iiodophenylalkyl amines in rat brain. J. nucl. Med. 1980; 21: 940-6.

Recent Developments in the Field of 123I-Radiopharmaceuticals [*]

Autoren

Recent Developments in the Field of ¹²³I-Radiopharmaceuticals ^[*]